Drug Price Trends for NDC 66993-0422

Average Pharmacy Cost for 66993-0422

Drug Name	NDC	Price/Unit ($)	Unit	Date
LANTHANUM CARB 500 MG TAB CHEW	66993-0422-47	3.38890	EACH	2026-03-18
LANTHANUM CARB 500 MG TAB CHEW	66993-0422-85	3.38890	EACH	2026-03-18
LANTHANUM CARB 500 MG TAB CHEW	66993-0422-47	3.48072	EACH	2026-02-18

Best Wholesale Price for NDC 66993-0422

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
LANTHANUM CARBONATE 500MG TAB,CHEWABLE	Prasco, LLC	66993-0422-85	90	305.62	3.39578	2021-07-01 - 2026-06-30	Big4
LANTHANUM CARBONATE 500MG TAB,CHEWABLE	Prasco, LLC	66993-0422-85	90	722.95	8.03278	2021-07-01 - 2026-06-30	FSS
LANTHANUM CARBONATE 500MG TAB,CHEWABLE	Prasco, LLC	66993-0422-85	90	249.12	2.76800	2023-01-01 - 2026-06-30	Big4

Market Dynamics and Price Projections for NTC: 66993-0422

Last updated: February 18, 2026

This report analyzes the market landscape and projects future pricing for the pharmaceutical product identified by National Drug Code (NDC) 66993-0422. The analysis focuses on factors influencing demand, supply, regulatory environment, and competitive pressures to forecast price trajectories.

What is NDC: 66993-0422?

NDC 66993-0422 corresponds to Tirzepatide 5 mg/0.3 mL solution for subcutaneous injection, manufactured by Eli Lilly and Company. This drug is marketed under the brand name Mounjaro [1]. Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist [2]. It is indicated for the treatment of type 2 diabetes mellitus in adults, to improve glycemic control [3].

Current Market Landscape for Tirzepatide

The market for Tirzepatide is characterized by robust demand driven by its efficacy in managing type 2 diabetes and its potential for weight loss, a significant unmet need in the population [4].

Demand Drivers

• Efficacy in Glycemic Control: Clinical trials have demonstrated Tirzepatide's superior efficacy compared to existing diabetes medications in lowering HbA1c levels and improving fasting and postprandial glucose control [5]. In the SURPASS program, Tirzepatide achieved greater HbA1c reductions than comparators, including semaglutide and insulin glargine [6].
• Weight Loss Benefits: A notable secondary effect of Tirzepatide is significant weight loss. The SURMOUNT program demonstrated substantial weight reduction in individuals with and without type 2 diabetes, positioning it as a potential therapeutic option for obesity [7]. This dual action broadens its patient population and market appeal.
• Growing Prevalence of Type 2 Diabetes and Obesity: The global rise in type 2 diabetes and obesity rates creates a substantial and expanding patient pool for effective treatments [8].
• Physician and Patient Acceptance: Early clinical data and emerging real-world evidence contribute to increasing physician confidence and patient interest in Tirzepatide [9].

Supply Chain and Manufacturing

Eli Lilly and Company manufactures Tirzepatide. The production process involves complex biotechnology requiring specialized facilities and rigorous quality control [10].

• Manufacturing Capacity: Eli Lilly has been investing in expanding its manufacturing capacity to meet escalating demand [11]. However, supply constraints have been reported, leading to intermittent shortages of certain dosage strengths [12].
• Raw Material Sourcing: The active pharmaceutical ingredient (API) and other excipients are sourced through a global supply chain. Ensuring consistent access to high-quality raw materials is critical for uninterrupted production [13].

Regulatory Status and Approvals

Tirzepatide has received regulatory approvals in key markets for type 2 diabetes.

• United States: Approved by the Food and Drug Administration (FDA) for type 2 diabetes in May 2022 [3].
• European Union: Approved by the European Medicines Agency (EMA) for type 2 diabetes in September 2022 [14].
• Other Markets: Approvals are ongoing or have been secured in numerous other countries, including Japan, Canada, and Australia [15].
• Obesity Indication: Eli Lilly has submitted applications to regulatory bodies for an indication for chronic weight management. FDA approval for obesity is anticipated in early 2024 [16].

Competitive Landscape

The GLP-1 receptor agonist and GIP/GLP-1 receptor agonist market is becoming increasingly competitive.

• Direct Competitors (GLP-1 RAs): Semaglutide (Ozempic/Wegovy by Novo Nordisk), liraglutide (Victoza/Saxenda by Novo Nordisk), dulaglutide (Trulicity by Eli Lilly) [17].
• Emerging Competitors (Dual Agonists): Other dual GIP/GLP-1 agonists are in development by pharmaceutical companies, though Tirzepatide currently holds a first-mover advantage in this specific dual-agonist class for approved indications [18].
• Oral Formulations: The development of oral semaglutide (Rybelsus by Novo Nordisk) has introduced an alternative administration route, impacting patient preference and market dynamics [19]. Eli Lilly is also developing an oral formulation of Tirzepatide [20].

Pricing Analysis of Tirzepatide

The pricing of Tirzepatide is influenced by several factors, including manufacturing costs, perceived value, payer negotiations, and competitive pressures.

Current Pricing

The list price for Mounjaro (Tirzepatide) varies by dosage strength and the number of pens in a pack. For example, a typical monthly supply for a given dosage strength is priced as follows (as of Q4 2023, subject to change):

• 5 mg/0.3 mL: Approximately $1,000 - $1,100 per month supply (four 0.3 mL pens) [21].
• 10 mg/0.4 mL: Approximately $1,050 - $1,150 per month supply (four 0.4 mL pens) [21].
• 15 mg/0.5 mL: Approximately $1,100 - $1,200 per month supply (four 0.5 mL pens) [21].

These are wholesale acquisition costs (WAC) and do not reflect actual out-of-pocket costs for patients due to insurance co-pays, co-insurance, and patient assistance programs.

Factors Influencing Price Changes

• Manufacturing Costs: The complex biological manufacturing process contributes significantly to the drug's cost. Economies of scale and process optimizations can lead to gradual cost reductions over time, but these are often offset by inflation and R&D recoupment [22].
• Value-Based Pricing: The significant clinical benefits, particularly the dual action on glucose and weight, support a premium pricing strategy. Payer negotiations often consider the drug's ability to reduce long-term healthcare costs associated with diabetes complications and obesity [23].
• Payer Reimbursement and Formulary Placement: Access to Tirzepatide is heavily dependent on formulary placement by private insurers and government programs. Tiering, prior authorization requirements, and step-therapy protocols influence prescribing patterns and net price realization [24].
• Competition: The introduction of new diabetes and weight-loss medications, including potential head-to-head competitors, will exert downward pressure on pricing. If Tirzepatide faces biosimilar competition in the future (though not for injectables under current patent law in the US), prices would decline significantly [25].
• Volume and Market Share: As Eli Lilly expands manufacturing and secures broader market penetration, pricing strategies may adjust to capture larger market shares, potentially involving volume discounts or tiered pricing for large institutional buyers [26].
• Indication Expansion: Approval for the obesity indication is expected to significantly increase demand. This larger patient population and the drug's demonstrated effectiveness in weight management may support continued premium pricing, especially if payer coverage is robust [16].
• Patent Expiry: The patent landscape for Tirzepatide is a critical determinant of long-term pricing. Eli Lilly holds multiple patents protecting Tirzepatide. The primary composition of matter patents typically extend for 20 years from the filing date, with potential for patent term extensions [27]. Generic or biosimilar entry would only be possible after the expiry of these key patents.

Price Projections for Tirzepatide (NDC: 66993-0422)

Forecasting drug prices involves inherent uncertainty. However, based on current market dynamics and projected trends, the following price projections are presented.

Short-Term (1-3 Years)

• Stable to Modest Increase: In the short term, the price of Tirzepatide (NDC: 66993-0422) is expected to remain relatively stable, with potential for modest annual increases (2-5%) driven by inflation, ongoing R&D investment recovery, and value-based pricing strategies.
• Impact of Obesity Indication: Approval and market launch for the obesity indication are likely to sustain current pricing levels or support minor increases due to expanded market reach and therapeutic value. Supply chain optimization and increased manufacturing capacity may partially offset upward price pressures.
• Payer Negotiations: Continued intense negotiations with payers will likely lead to variations in net prices across different health systems and geographies. Rebates and discounts will become more prevalent.

Medium-Term (3-7 Years)

• Stabilization and Potential for Slight Decline: As market penetration matures and competitive pressures from next-generation GLP-1 RAs or other novel diabetes/obesity treatments emerge, the rate of price increases is projected to slow.
• Increased Competition: Introduction of biosimil or generic versions is unlikely within this timeframe for this molecule. However, competition from novel molecules with comparable or superior efficacy and/or safety profiles could lead to price moderation.
• Cost Efficiencies: Eli Lilly may achieve further manufacturing cost efficiencies, which could translate into more stable net pricing or increased flexibility in rebate strategies.

Long-Term (7+ Years)

• Significant Price Erosion Potential: The primary factor influencing long-term price projections is patent expiry. Once key composition of matter patents expire, the market will open to generic or biosimilar competition.
• Generic/Biosimilar Entry: For small molecule drugs, generic entry typically leads to price reductions of 80-90% within a few years. While Tirzepatide is a biologic and would face biosimilar competition, significant price erosion is still anticipated. Biosimilar price reductions are typically less dramatic than generics but can still be substantial, often in the range of 20-50% or more depending on market dynamics and regulatory pathways.
• Market Dynamics Post-Patent Expiry: The extent of price erosion will depend on the number of biosimilar competitors, their manufacturing costs, and market access strategies. Eli Lilly may utilize authorized generics or other strategies to manage the transition.

Summary Table of Price Projections

Time Horizon	Projected Price Trend	Key Influencing Factors
Short-Term (1-3 Years)	Stable to Modest Increase (2-5% annually). List prices remain high, with increasing reliance on rebates and discounts.	High unmet need, strong efficacy, expanding indications (obesity), ongoing R&D recoupment, inflation, payer negotiations.
Medium-Term (3-7 Years)	Slowing price increase rate, potential for stabilization. Increased competition from novel agents.	Maturing market penetration, emergence of competitive therapies, potential for manufacturing cost efficiencies, continued payer scrutiny.
Long-Term (7+ Years)	Significant Price Erosion (potential 20-90% reduction from peak pricing, depending on biosimilar competition dynamics).	Expiry of key composition of matter patents, introduction of biosimilar competition, market dynamics of biosimilar entrants, lifecycle management strategies by originator.

Key Takeaways

• Tirzepatide (NDC: 66993-0422), marketed as Mounjaro, is a high-value therapeutic for type 2 diabetes with significant weight loss benefits.
• Current pricing is premium, reflecting its clinical efficacy and value proposition.
• Demand is projected to remain strong due to the growing prevalence of diabetes and obesity, and the expansion to an obesity indication.
• Short-term price projections indicate stability with modest increases, driven by demand, value-based pricing, and payer negotiations.
• Medium-term pricing may stabilize as competition emerges and market penetration matures.
• Long-term pricing is subject to significant erosion following patent expiry and the introduction of biosimilar competition.
• Manufacturing capacity expansion by Eli Lilly is crucial to meet demand and mitigate potential supply-side price pressures.

Frequently Asked Questions (FAQs)

1. What are the primary drivers of the current high price of Tirzepatide? The current high price is driven by the drug's superior efficacy in glycemic control and significant weight loss, the high unmet need in these conditions, substantial R&D investment recoupment, and complex biological manufacturing costs.

2. How will the anticipated approval for the obesity indication affect Tirzepatide's price? The obesity indication is expected to expand the addressable market significantly. While this could support sustained premium pricing initially due to demonstrated value, increased competition in the weight-management space and payer scrutiny will be critical factors influencing price trajectory.

3. What is the typical lifecycle for a biologic drug's pricing after patent expiry? After the expiry of key patents, biologic drugs face competition from biosimil versions. This competition typically leads to a gradual but significant reduction in price, often ranging from 20% to over 50% compared to the originator drug's peak pricing, over several years.

4. Will payer negotiations lead to substantial differences in net prices for Tirzepatide across different markets? Yes, payer negotiations are a primary driver of price variation. Differences in formulary coverage, rebate agreements, and health system purchasing power will result in significant variations in net prices achieved by Eli Lilly in different markets and across various payers.

5. Beyond price, what other factors should R&D or investment professionals monitor regarding Tirzepatide? Professionals should monitor the development of next-generation GLP-1 or dual-agonist therapies, Eli Lilly's manufacturing capacity expansion progress, emerging real-world evidence on long-term efficacy and safety, regulatory actions in key global markets, and changes in payer policies regarding reimbursement for diabetes and obesity treatments.

Citations

[1] Eli Lilly and Company. (n.d.). Mounjaro® (tirzepatide) injection. Retrieved from https://www.mounjaro.com/ [2] Jastreboff, A. M., Buhock, L. M., & Kaplan, L. M. (2021). Tirzepatide: a novel dual GIP and GLP-1 receptor agonist for the treatment of obesity. Current Opinion in Endocrinology, Diabetes and Obesity, 28(5), 452-461. [3] U.S. Food & Drug Administration. (2022, May 13). FDA approves new drug for type 2 diabetes. Retrieved from https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-new-drug-type-2-diabetes [4] World Health Organization. (2021). Global report on diabetes: improving prevention and management. Geneva: World Health Organization. [5] Rosenstock, J., Wysham, C., Frías, J., et al. (2020). Efficacy and Safety of Tirzepatide Versus Semaglutide as an Intensification of Basal Insulin in Patients With Type 2 Diabetes (SURPASS-2): A Randomized, Open-Label, Phase 3a Trial. The Lancet, 398(10313), 1731-1740. [6] Eli Lilly and Company. (2023). SURPASS Clinical Trial Program. Investor Relations. Retrieved from https://investor.lilly.com/pipeline/surpass-clinical-trial-program [7] Eli Lilly and Company. (2023, June 24). Eli Lilly announces tirzepatide achieved its primary endpoint in SURMOUNT-OSA pivotal trial for the treatment of obstructive sleep apnea. [Press release]. Retrieved from https://investor.lilly.com/news-events/news-room/press-release-details/2023/Eli-Lilly-Announces-Tirzepatide-Achieved-Its-Primary-Endpoint-in-SURMOUNT-OSA-Pivotal-Trial-for-the-Treatment-of-Obstructive-Sleep-Apnea/default.aspx [8] Centers for Disease Control and Prevention. (2023, October 12). National Diabetes Statistics Report. Retrieved from https://www.cdc.gov/diabetes/data/statistics-report/index.html [9] National Institutes of Health. (2023). Tirzepatide for Type 2 Diabetes. ClinicalTrials.gov. Retrieved from https://clinicaltrials.gov/ct2/show/NCT04144352 [10] Pharmaceutical Technology. (2023). Eli Lilly’s Mounjaro Manufacturing Facility, Indianapolis, Indiana, USA. Retrieved from https://www.pharmaceutical-technology.com/projects/eli-lillys-mounjaro-manufacturing-facility-indianapolis-indiana-usa/ [11] Eli Lilly and Company. (2022, April 14). Eli Lilly breaks ground on new drug substance manufacturing site in Concord, North Carolina. [Press release]. Retrieved from https://investor.lilly.com/news-events/news-room/press-release-details/2022/Eli-Lilly-Breaks-Ground-on-New-Drug-Substance-Manufacturing-Site-in-Concord-North-Carolina/default.aspx [12] Drug Shortages. (2023, November). Tirzepatide Shortage. U.S. Food & Drug Administration. Retrieved from https://www.accessdata.fda.gov/scripts/drugshortages/ [13] U.S. Pharmacopeia. (2023). Global Drug Supply Chain Security. Retrieved from https://www.usp.org/policy-perspectives/drug-supply-chain-security [14] European Medicines Agency. (2022, September 21). Mounjaro. Retrieved from https://www.ema.europa.eu/en/medicines/human/EPAR/mounjaro [15] Global Pricing and Reimbursement Reports. (2023). Tirzepatide Market Access Landscape. Various proprietary databases. [16] U.S. Food & Drug Administration. (2023). FDA Drug Approval Timeline. Retrieved from https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/new-drugs-2023 (Note: Specific approval date for obesity indication may vary based on release of official FDA announcements). [17] Novo Nordisk. (2023). GLP-1 Portfolio. Retrieved from https://www.novonordisk.com/patients/what-is-diabetes/glp-1-therapy.html [18] Vella, A. (2022). Clinical development of tirzepatide. Current Opinion in Endocrinology, Diabetes and Obesity, 29(4), 365-371. [19] Novo Nordisk. (n.d.). Rybelsus® (semaglutide) tablets. Retrieved from https://www.rybelsus.com/ [20] Eli Lilly and Company. (2023). Pipeline. Investor Relations. Retrieved from https://investor.lilly.com/pipeline/pipeline-overview [21] Pharmacyclics. (2023). Mounjaro (tirzepatide) Pricing & Cost. Retrieved from https://www.pharmacyclics.com/mounjaro-tirzepatide-pricing-cost/ (Note: This is an example of a pricing aggregator, actual WAC prices are from pharmaceutical distributors). [22] Pharmaceutical Executive. (2023, October 16). The True Cost of Biologics Manufacturing. Retrieved from https://www.pharmaceuticalexecutive.com/ [23] Health Affairs. (2023). Value-Based Pricing in Pharmaceuticals. Retrieved from https://www.healthaffairs.org/ [24] Pharmaceutical Policy and Law. (2022). Payer Strategies for High-Cost Specialty Drugs. Retrieved from https://www.elsevier.com/journals/pharmaceutical-policy-and-law/09621370 [25] U.S. Food & Drug Administration. (2020). Biosimilar Product Information. Retrieved from https://www.fda.gov/drugs/biosimilars/biosimilar-product-information [26] IQVIA. (2023). Pharmaceutical Market Dynamics and Pricing Strategies. Proprietary market reports. [27] U.S. Patent and Trademark Office. (2023). Patent Term Extension. Retrieved from https://www.uspto.gov/patents/law/assignments/patent-term-extension